Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by Hironaga Satake
Correction: A Phase II Trial of 1st-Line Modified-Folfoxiri Plus Bevacizumab Treatment for Metastatic Colorectal Cancer Harboring RAS Mutation: JACCRO CC-11
Oncotarget
Oncology
Related publications
Phase II Randomized Trial of Sequential or Concurrent FOLFOXIRI‐Bevacizumab Versus FOLFOX‐Bevacizumab for Metastatic Colorectal Cancer (STEAM)
Oncologist
Cancer Research
Medicine
Oncology
Metastatic Colorectal Cancer First-Line Treatment With Bevacizumab: The Impact of K-Ras Mutation
OncoTargets and Therapy
Oncology
Pharmacology
A Multicenter Clinical Phase II Study of FOLFOXIRI Plus Bevacizumab as First-Line Therapy in Patients With Metastatic Colorectal Cancer: QUATTRO Study
Clinical Colorectal Cancer
Oncology
Gastroenterology
S‐1 Plus Raltitrexed for Refractory Metastatic Colorectal Cancer: A Phase II Trial
Oncologist
Cancer Research
Medicine
Oncology
A Phase 2 Randomised Study of Veliparib Plus FOLFIRI±bevacizumab Versus Placebo Plus FOLFIRI±bevacizumab in Metastatic Colorectal Cancer
British Journal of Cancer
Cancer Research
Oncology
The Clinical Benefit of Bevacizumab in Metastatic Colorectal Cancer Is Independent of K-Ras Mutation Status: Analysis of a Phase III Study of Bevacizumab With Chemotherapy in Previously Untreated Metastatic Colorectal Cancer
Oncologist
Cancer Research
Medicine
Oncology
A Phase II Study of Oxaliplatin, Dose-Intense Capecitabine, and High-Dose Bevacizumab in the Treatment of Metastatic Colorectal Cancer
Clinical Colorectal Cancer
Oncology
Gastroenterology
"Poker" Association of Weekly Alternating 5-Fluorouracil, Irinotecan, Bevacizumab and Oxaliplatin (FIr-B/FOx) in First Line Treatment of Metastatic Colorectal Cancer: A Phase II Study
BMC Cancer
Cancer Research
Oncology
Genetics
A Phase II Trial of Erlotinib in Combination With Bevacizumab in Patients With Metastatic Breast Cancer
Clinical Cancer Research
Cancer Research
Oncology
